Stage-wise variation in serum C-reactive protein and cardiovascular risk in chronic kidney disease of uncertain etiology among Sri Lankans; a preliminary study Authors: Hansani Niroshika, Harshi Weerakoon, Nalaka Herath, Sujani Premathilake, Prasad Jayasooriya, Kosala Weerakoon Published: 2026 ABSTRACT AbstractBackgroundChronic kidney disease of uncertain etiology (CKDu) is a progressive nephropathy histologically characterized by tubulointerstitial fibrosis with varying degrees of inflammatory infiltrations. C-reactive protein (CRP) is an acute phase protein that serves as a marker of systemic inflammation and cardiovascular disease (CVD) risk. Therefore, this study aimed to evaluate serum CRP levels in patients with CKDu and to assess their association with renal function and CVD risk.MethodsA cross-sectional study was conducted on 40 clinically diagnosed CKDu patients at different severity stages (stage 2 (n = 5, 12.5%), stage 3A (n = 8, 20.0%), stage 3B (n = 10, 25.0%), stage 4 (n = 10, 25.0%), and stage 5 (n = 7, 17.5%). As the control group, age and sex matched 16 apparently healthy individuals (mean age 52.19 ± 10.26 years, 56.2% male) were recruited. CRP concentrations were measured using immunoturbidimetry (range 0-150 mg/L), and CVD risk was categorized based on CDC/AHA guideline. Patients with CRP > 10 mg/L were excluded to minimize confounding from potential underlying infections.ResultsCRP levels across CKDu stages demonstrated a nonlinear trend with significant peak at stage 3A (1.6 mg/L; IQR: 1.08–2.95), compared to their matched control subjects (0.50 mg/L; IQR 0.30–1.73; p = 0.0045), followed by a decline in later stages. No significant association was observed between CRP and eGFR (r = 0.11, 95% CI -0.21 to 0.41, p = 0.49). After classifying the CKDu patients for CVD risk, Stage 3A patients had higher odds of increased CVD risk than controls (odds ratio = 21.0, p = 0.0236) followed by stage 3B (odds ratio = 13.5, p = 0.0352). Further, CVD risk stratification was not confounded by age, sex, and renal function indicators (eGFR and serum creatinine).ConclusionElevated CRP levels and associated CVD risk in CKDu patients appear most pronounced in intermediate disease stages (3A-3B), providing a rationale for a large longitudinal study.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13104-026-07914-3.Keywords: CVD risk, CRP, Chronic kidney disease of uncertain etiology, CKDu, Inflammation Introduction C-reactive protein (CRP) is an acute-phase reactant predominantly synthesized by hepatocytes with additional contributions from smooth muscle cells and immune cells, like macrophages and lymphocytes [1]. Particularly in kidney diseases, CRP expression has also been reported in the renal tubular epithelial cells and endothelial cells [2]. Its production is upregulated by proinflammatory cytokines, including interleukin (IL) -6 and tumor necrosis factor alpha (TNF-α), key mediators of the inflammatory response. CRP functions as a mediator of the innate immune response, triggering the complement system and phagocytosis by binding to damaged or dying cells and pathogens. Through these mechanisms, CRP facilitates the removal of cellular debris and microbes [3]. Clinically, CRP serves as a biomarker of acute inflammation with secretion occurring at the initial phase of the inflammatory response (4–10 h) and peak plasma levels observed around 48 h, reflecting the intensity and persistence of the inflammatory process. It has a half-life of 19 h [4]. Beyond its utility as a biomarker of acute infection, CRP itself exhibits intrinsic proinflammatory activity. These proinflammatory effects can manifest as a localized inflammatory exacerbation by enhancing leukocyte recruitment, complement activation, and inducing other proinflammatory cytokines [3, 5]. These effects can predispose to endothelial dysfunction, oxidative stress, fibrosis, and inflammation, all of which are related to the pathogenesis of chronic non-communicable diseases, including chronic kidney disease (CKD) and cardiovascular diseases (CVDs) [6]. Chronic kidney disease of uncertain etiology (CKDu) is a nephropathy predominantly observed in resource-limited agricultural communities, mainly in Central America and Sri Lanka [7]. Though exposure to environmental and occupational hazards such as agrochemicals, heavy metals, and recurrent dehydration have been identified as associated factors, the exact etiological factors and the pathophysiology are yet to be defined [8]. However, early proximal tubular damage marked by distinct lysosomal aggregates in CKDu is suggestive of premature cellular senescence due to nephrotoxin exposure [9, 10]. These senescent cells may subsequently result in release of proinflammatory cytokines inducing both hepatic and localized CRP secretion [11]. Experimental evidence suggests that elevated CRP can induce renal inflammation primarily through activation of the nuclear factor kappa B (NF-κB) pathway and fibrosis through extracellular signal-regulated kinase (ERK)/p38 and transforming growth factor-β1 (TGF-β1) pathways through Smad3 phosphorylation [12]. However, its direct role in CKDu pathogenesis remains unclear. But the involvement of inflammatory and degenerative processes in CKDu is evidenced by histopathological findings that typically reveal characteristic features of tubulointerstitial damage, including tubular atrophy, interstitial fibrosis, and mononuclear cell infiltration [13]. Although inflammation and fibrosis play a significant role in the pathogenesis and progression of CKDu, there is a paucity of studies to evaluate the role of systemic inflammatory markers, including CRP, in patients with CKDu. Systemic inflammation may represent a key mechanism driving renal cellular injury while concurrently increasing CVD risk in this population. Given the limited existing data on systemic inflammatory markers across CKDu stages, this study was designed as an exploratory, hypothesis-generating analysis rather than a definitive estimation of effect size. Accordingly, this preliminary study assessed stage-wise variation in serum CRP levels, in patients with CKDu and assessed the association between CRP-defined systemic inflammation and cardiovascular disease risk across disease stages. Methodology This study was designed as an exploratory, stage-stratified cross-sectional observational analysis to examine patterns of systemic inflammation, as assessed by CRP, across stages of CKDu. The study was conducted among already diagnosed CKDu patients on regular follow-up (between April and August 2024) at the nephrology unit, Teaching Hospital, Kurunegala, Sri Lanka, and apparently healthy individuals served as the control. Ethical approval for the study was obtained from the Ethics Review Committee, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka (ERC/2023/16). Definitions The following case definitions were used in patient recruitment and CRP-based CVD risk assessment. CKDu Having evidence of CKD in the absence of known etiological factors such as diabetes, hypertension, polycystic kidney disease, congenital malformations, autoimmune diseases, or glomerular diseases. Diagnostic criteria include an estimated glomerular filtration rate (eGFR) < 60 mL/min per 1.73m2 using the chronic kidney disease epidemiology collaboration (CKD-EPI) equation and markers of kidney damage in urine, either urine albumin to creatinine ratio (UACR) ≥ 30 mg/g or protein to creatinine ratio (PCR) ≥ 150 mg/g. These findings should be confirmed on repeat assessment after at least 12 weeks to establish chronicity, and further confirmed with histopathology and ultrasound evidence consistent with CKDu where available [14]. Biopsy confirmation of CKDu Appearances of chronic interstitial nephritis, interstitial inflammation, and tubular atrophy in the cortical area [15]. Ultrasound characteristics of CKD Small-sized kidneys with increased echogenicity and altered cortico-medullary demarcation [16]. CKD staging according to the national kidney foundation guidelines [17] Classification based on eGFR (stage 2: 60–89 mL/min/1.73m2, stage 3A: 45–59 mL/min/1.73m2, stage 3B: 30–44 mL/min/1.73m2, stage 4: 15–29 mL/min/1.73m2, stage 5: <15 mL/min/1.73m2 or undergoing dialysis). CRP-based CVD risk assessment Measuring CRP (in mg/L) in individuals without symptoms and signs of infection or inflammation and subsequent categorizing into risk groups as low risk (CRP < 1 mg/L), moderate risk (CRP 1–3 mg/L), and high risk (CRP > 3 mg/L). Individuals with CRP values > 10 mg/L should be excluded from risk categorization, as they may indicate an underlying infection or inflammatory condition. In such cases, repeat testing is advised after 2 weeks [18]. Study population and sampling Both male and female patients with a confirmed CKDu diagnosis attending the routine nephrology clinic were selected consecutively until a minimum of 10 samples were obtained for each stage of disease severity (staging at this step was based on the most recent laboratory findings available in clinical records. The staging was confirmed by re-calculating the eGFR values using the serum creatinine values obtained from freshly collected blood samples). Patients undergoing dialysis, who had received kidney transplantation, or who had an acute infection during the last 2 weeks were excluded. The control group was recruited based on a preliminary screening criterion: no history of renal disease and no recent acute illness over the prior 2 weeks. To ensure comparability, the age range of CKDu patients was divided into 5-year intervals. Controls were selected proportionally from each age group to match the age- and sex-distribution of the CKDu group. A specific sample size calculation was not undertaken, as the study was not intended to provide definitive estimates of effect size or population-level inference. Instead, the sample size was determined a priori based on feasibility, availability of well-defined CKDu participants, and the objective of generating preliminary, stage-specific insights into systemic inflammatory dynamics. The balanced allocation of participants across CKDu stages was prioritized to facilitate internal comparability and trend identification. Findings are therefore interpreted as hypothesis-generating, intended to be designing of larger, well controlled, adequately powered studies. Participant data and sample collection Informed written consent was obtained from all participants before the data and sample collection. The demographic data, medication history, and disease history were obtained using an interviewer-administered structured questionnaire and cross verified by referring to clinical records. A 2 mL peripheral venous blood sample was obtained from each participant for analyzing serum creatinine and CRP. In addition, an early morning urine sample was collected to assess UACR in control subjects to confirm the normal renal functional status. Only individuals with an eGFR ≥ 90 and UACR < 30 mg/g were included in the control group. Laboratory analysis and categorization The whole blood samples collected were kept at room temperature for 30 min, allowing them to clot, and kept on ice until transported to the laboratory. The serum was separated by centrifugation (1200 g for 10 min) and stored at -80 °C till further analysis. All assays were performed in an accredited laboratory, using a Biosystems BA400 automated analyzer according to the manufacturer’s instructions, adhering to the specified quality control measures (Supplementary file 1). Serum creatinine was estimated using compensated Jaffe assay to calculate the eGFR [19]. Accordingly, the patients were categorized into different severity stages (from stages 2–5). CRP was measured by a high sensitivity immunoturbidimetric latex agglutination assay (assay range 0-150 mg/L) to categorize the patients into three CVD risk groups. UACR was calculated using urine albumin (immunoturbidimetry, mg/L) and creatinine (compensated Jaffe assay, mg/dL) values. Statistical analysis Statistical analysis was performed using GraphPad Prism (Version 9.5 for Windows, GraphPad Software, Boston, Massachusetts USA, www.graphpad.com) software and R studio (version 4.4.3) packages: ggplot2, tidyverse, meta). Continuous variables were expressed as median with interquartile range or mean ± standard deviation (SD) as appropriate. The Mann-Whitney U and Kruskal-Wallis tests were used to compare the medians between groups, followed by Dunn’s multiple comparisons test for subsequent assessment of pairwise differences. Categorical variables were reported as frequencies and percentages, with comparisons performed using the Fishers exact test. Odds ratios (ORs) were calculated to compare the likelihood of the participants being in different CVD risk groups based on CRP levels. The Random effect model was used to estimate a pooled OR to summarize the overall association between CKDu status and CVD risk. In statistical analyses, p < 0.05 was considered significant. Results Characteristics of the study group and participant inclusion A total of 47 patients with confirmed CKDu were recruited, consisting of 41 males (87.2%) and 6 females (12.8%), with an age range of 33–78 (mean age 55.89 ± 10.54) years. CKDu was confirmed by biopsy in 22 (46.8%) patients. The control group (n = 16, mean age of 52.19 ± 10.26 years) included 9 males (56.2%). Among the CKDu patients, 7 (14.9%) had clinically confirmed comorbidities, including two with hyperthyroidism (4.3%), one patient each (2.1%) with bronchial asthma, gastro-esophageal reflux disease, ulcerative colitis, and ST-elevation myocardial infarction (Fig. 1A). These patients were excluded to eliminate potential confounding effects on CRP levels. Therefore, the final cohort included 40 patients (stage 2 (5, 12.5%), stage 3 A (8, 20%), stage 3B (10, 25%), stage 4 (10, 25%), and stage 5 (7, 17.5%). Among them, 31 (77.5%) had CRP levels above 1 mg/L, indicating moderate to high CVD risk. A Distribution of CKDu patients with and without comorbidities and corresponding CVD risk levels B Age and gender of patients with CKDu across different disease stages C Comparison of CRP levels between CKDu stages and healthy controls D Correlation between estimated glomerular filtration rate and CRP E Frequency distribution of CVD risk categories across CKDu stages. F Forest plot showing odds ratios for CVD risk across CKDu stages compared to controls. HCM: hypertrophic cardiomyopathy, STEMI: ST elevation myocardial infarction, GERD: gastro-esophageal reflux disease, CRP: C-reactive protein, C: control, eGFR: estimated glomerular filtration rate, CVD: cardiovascular disease A male predominance was observed across all CKDu stages (Fig. 1B). Therefore, to ensure optimal comparability, subsets of age- and gender-matched control subjects were selected from the total of 16 available controls for each disease stage during pairwise comparisons. CRP-based CVD risk among CKDu patients Analysis of CRP levels across individual disease stages revealed that stage 3A had a significantly elevated median CRP level (1.6 mg/L; IQR: 1.08–2.95) compared to matched controls (0.50 mg/L; IQR: 0.30–1.73; p = 0.0045, Mann-Whitney U test). Further, CRP levels were higher in CKDu patients across all stages compared to matched controls, though not statistically significant at the 95% confidence level. The overall distribution highlights a non-linear trend of CRP levels across CKDu stages, with a notable and significant peak at stage 3 A, followed by a decline in later stages (Fig. 1C). Correlation analysis did not show a significant association between CRP and eGFR (r = 0.11, 95% CI -0.21 to 0.41, p = 0.49, Fig. 1D). When patients were stratified into CVD risk groups based on CRP values as, most of the patients in stage 3A (7, 87.5%) and 3B (9, 90.0%) had moderate to high CVD risk compared to their matched controls (3 A: 2, 25.0% and 3B: 4,40%). Of the patients with high CVD risk (n = 7), 6 (86%) were in these two CKD stages (Fig. 1E; Table 1). To further investigate this, ORs were calculated to compare the likelihood of being in the moderate to high CVD risk group (CRP > 1 mg/L) versus the low-risk group (CRP < 1 mg/L) among CKDu patients stratified by CKD stage and age/sex matched controls. Notably, patients in stages 3A (OR 21.0; 95% CI 1.5-293.3) and 3B (OR 13.5; 95%CI 1.2-152.2) demonstrated significantly high odds of higher CVD risk than control subjects. The random effect model yielded a pooled OR of 3.91 (95% CI: 0.63–24.13), indicating an overall trend toward higher odds of CVD risk in CKDu patients than controls, although not reaching statistical significance at 95% confidence. The wide confidence and prediction intervals (0.23–67.71) reflect high uncertainty and variability in effect size, likely influenced by small sample sizes and heterogeneity in stage-specific associations (Fig. 1F). Overall, these results suggest a potential increase in systemic inflammation in intermediate stages of CKDu. There were no significant differences among CVD risk groups in baseline demographics or renal function indicators, including age, gender, serum creatinine, and eGFR, suggesting that CRP elevation was not confounded by these factors (Table 1). Table 1Baseline demographics and renal functions of patients with different CVD risk categories (n = 40)Low risk(< 1 mg/L)n = 9Moderate risk(1–3 mg/L)n = 24High risk(> 3 mg/L)n = 7P valueAge (years)57.11 ± 10.9655.25 ± 11.4154.43 ± 6.630.9241SexMale81970.3802Female150Serum creatinine (mg/dL)2.70 ± 1.552.64 ± 1.362.28 ± 1.660.4111eGFR (mL/min/1.73 m2)36.33 ± 21.9535.13 ± 20.6644.14 ± 16.090.4291Stage22 (40.0%)3 (60.0%)0 (0%)0.15923A1 (12.5%)3 (37.5%)4 (50.0%)3B1 (10.0%)7 (70.0%)2 (20.0%)44 (40.0%)6 (60.0%)0 (0.0%)51 (14.3%)5 (71.4%)1 (14.3%)CKDu: chronic kidney disease of uncertain etiology; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein, ¹Kruskal-Wallis test, ²Chi-square test Baseline demographics and renal functions of patients with different CVD risk categories (n = 40) CKDu: chronic kidney disease of uncertain etiology; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein, ¹Kruskal-Wallis test, ²Chi-square test Discussion The current study, which examined variations in CRP levels across different stages of CKDu demonstrated an apparent non-linear pattern with a peak at stage 3A followed by a decline in later stages. Notably, the highest CRP levels were detected in stages 3A and 3B, suggesting a potential association with disease activity at these stages. Further, CVD risk stratification revealed that patients in stages 3A and 3B were more likely to have moderate to high CVD risk compared to their age and sex matched controls. Owing to small sample size, these findings need to be considered as preliminary and hypothesis generating observations which require further validation. The observed CRP pattern in CKDu appeared to differ from that seen in known CKDs including diabetic nephropathy (DN). In DN, the mean CRP levels rise steadily from 5.1 mg/L in early disease stages (stage 2) to 13.1 mg/L in advanced stages (stage 5) [20], reflecting the persistent inflammatory response driven by metabolic and hemodynamic stressors, including chronic hyperglycemia, oxidative stress, and advanced glycation end products (AGE) that activate vascular, immune, and glomerular cells [21]. This steady elevation of CRP in DN might be due to sustained elevation of proinflammatory cytokines such as IL-6, TNF α, IL-1β, with IL-6 serving as the primary inducer of hepatic CRP [22, 23]. In contrast, CKDu patients in the present study showed an apparent surge of CRP at stage 3A and a subsequent decline with advanced disease. This preliminary observation can be supported by multiple evidence from previous studies as discussed below. Histopathological findings from both asymptomatic and symptomatic patients, and stage-specific observations, support the fact that inflammation in CKDu is transient rather than a persistent process. Asymptomatic patients at early stages are often identified through screening or incidental findings despite the presence of interstitial fibrosis, even in stages 1 and 2, often without significant inflammation [24, 25]. In contrast, symptomatic CKDu patients who present with backache, fatigue, dysuria, and joint pain show higher levels of inflammatory markers, including elevated CRP, erythrocyte sedimentation rate (ESR), along with histological evidence of higher interstitial lymphocytic infiltration and tubulitis [26]. This symptomatic presentation is most consistent with the phase of transient systemic inflammation, corresponding to stage 3, and it might explain why higher number of newly diagnosed patients are detected at this stage [27]. Stage specific histopathological observations further support this, since stage 3 shows progressive tubular interstitial damage, with moderate to severe interstitial fibrosis accompanied by increased lymphocytic infiltrations. However, in more advanced stages (stage 4,5), the active inflammation persists (although not mirrored by CRP) but with a higher degree of interstitial fibrosis, tubular atrophy, and glomerulosclerosis [25]. CKDu is characterized by early tubular injury rather than glomerular injury as reflected by elevated urinary biomarkers of tubular injury, including α1 macroglobulin [28], neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1) [29] along with ultrastructural features of premature cellular senescence in proximal tubular epithelial cells (PTECs), such as lysosomal aggregates, mitochondrial swelling and cellular detachment [9, 30] even in early stages of the disease. Tubular cell injury and subsequent premature tubular cell senescence can result in a senescent-associated secretory phenotype (SASP) that are capable of producing profibrotic and proinflammatory cytokines [31], might underlie the peak IL-6, monocyte chemoattractant protein (MCP-1) at stage 3 CKDu patients [32]. This IL-6 surge that is known to induce hepatic CRP production may provide a possible biological explanation for higher CRP observed at intermediate stages in our study. Simultaneously, localized processes, including monomeric CRP (mCRP) production by tubular cells and infiltrating macrophages [2], may sustain continuous immune activity in kidney without significantly elevating systemic pentameric CRP (pCRP) during advanced stages. As the disease progresses, the renal microenvironment shift towards severe fibrosis [25]. Transforming growth factor β (TGF-β), a central mediator of fibrosis is upregulated in CKDu patients [33], and can be secreted directly by senescent tubular cells [34] or activated indirectly via CRP [35]. Once activated, it also induces the epithelial to mesenchymal transition and endothelial-mesenchymal transition, amplifying fibrosis through myofibroblast formation. Apart from the fibrosis induction, TGF-β also has an anti-inflammatory activity via macrophage polarization to an anti-inflammatory phenotype, inhibiting pro-inflammatory cytokines and inhibiting inflammatory signaling pathways [36, 37]. Therefore, this dual action may explain the coexistence of progressive fibrosis with lower systemic CRP levels in advanced CKDu. However this requires mechanistic validation. CKD due to known aetiologies like diabetes, hypertension, and metabolic dysfunction are well-established drivers of chronic low grade inflammation [38]. Therefore, CVD risk is high in CKD patients regardless of the severity stage [39] and accounts for approximately 40% of hospitalizations and 50% mortality across all stages of the disease [40]. Though the CVD risk in CKDu based on CRP was barely explored, the risk assessed through other risk assessment tools like World Health Organization/Pan American Health Organization (WHO/PAHO) identified low (< 10%) 10 year CVD risk among CKDu patients [41]. This lower predicted risk also aligns with low arterial stiffness [42], lower prevalence of left ventricular hypertrophy and hypertension in CKDu patients compared to CKDs of known aetiologies [41]. CRP is already recognized as an established marker of systemic inflammation and CVD risk. The present study evaluated the CVD risk of CKDu patients in Sri Lanka based on CRP, in whom CVD risk is often assessed using similar CVD risk indicators for CKDs of known aetiologies. If validated in larger studies, this approach may help in capturing more patients with inflammatory related CVD risk. In this cohort, as per the CRP levels, only 17.5% had a high CVD risk. Subgroup analysis further revealed that moderate to high CVD risk was more frequent among those with intermediate stages of CKDu. This observation appears to differ from CKDs of known aetiologies, which reflects a significant increase in CVD risk, regardless of the severity stage [39]. These preliminary findings suggest a distinct CVD risk pattern among patients with CKDu and requires validation in a lager cohort. Limitations This study has several limitations in assessing CRP. Participants with CRP levels exceeding 10 mg/L were excluded to minimize confounding from clinically undiagnosed acute inflammatory conditions. Although repeated CRP measurements obtained at lease two weeks apart are recommended to account for transient inflammatory fluctuations [43], logistical constraints limited assessment to a single measurement, which may not fully capture within-individual variability over time. As a preliminary, single-centre study, the sample size was small (n = 40), with a limited number of controls (n = 16), a male-predominant cohort, and imbalance across CKDu stage specific subgroups. These factors limit statistical power, precision of estimates, and generalizability of the findings. Accordingly, the observed variation in CRP across CKDu stages should be interpreted as exploratory and hypothesis generating rather than confirmatory. Additionally, only a subset of patients underwent biopsy confirmation of CKDu and although standard clinical criteria were applied, incomplete histopathological confirmation may have introduced some diagnostic heterogenicity. CRP is influenced by multiple demographic, clinical, lifestyle, and environmental factors. While major sources of confounding were minimized through exclusion of participants with acute infections, inflammatory disorders, and metabolic diseases, residual confounding cannot be excluded. Data on several important determinants of systemic inflammation and cardiovascular risk, including adiposity, smoking status, lipid profile, medication use, and environmental exposures were not comprehensively incorporated into the analysis. Consequently, the study population was not phenotypically characterized, and the observed associations should be interpreted with caution. Finally, the cross-sectional design precluded assessment of temporal changes in CRP and disease progression, and no independent validation cohort was available. However, the study was intentionally designed as an exploratory investigation to examine systemic inflammation across CKDu stages using a well-established inflammatory biomarker. Despite these limitations, this exploratory analysis provides preliminary evidence supporting a potential association between CKDu and systemic inflammation and highlights the need for larger, longitudinal, multicenter studies incorporating comprehensive clinical, epidemiological, and environmental characterization. Conclusions This exploratory study observed variation in CRP levels across different stages of CKDu, with an apparent surge in stages 3A-3B, with a subsequent decline in advanced stages. Correspondingly, the CRP-defined CVD risk appeared to be high in stages 3A and 3B. Therefore, the intermediate stages (3A-3B) seem to be an important window for timely interventions. Further longitudinal studies would be pivotal in clarifying the role of CRP in CKDu progression and its potential as a CKDu-specific CVD risk marker. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 2. Acknowledgements We acknowledge the patients, the staff of the Nephrology Unit, Teaching Hospital, Kurunegala, and the data collectors for their support and contributions to this study. Abbreviations Advanced glycation end-products Confidence interval Chronic kidney disease Chronic kidney disease epidemiology collaboration Chronic kidney disease of uncertain etiology C-reactive protein Cardiovascular disease Diabetic nephropathy Estimated glomerular filtration rate Extracellular signal-regulated kinase Erythrocyte sedimentation rate Interquartile range Interleukin Kidney injury molecule-1 Monocyte chemoattractant protein-1 Nuclear factor kappa-light-chain-enhancer of activated B cells Neutrophil gelatinase-associated lipocalin Odds Ratio Pan American Health Organization Protein-to-creatinine ratio Proximal tubular epithelial cell Senescence-associated secretory phenotype Transforming growth factor beta Tumor necrosis factor Urine albumin-to-creatinine ratio World Health Organization Author contributions HN contributed to sample and data collection, analysis, and writing the original draft, HW contributed to the conceptualization of the study, and participated in reviewing, editing, and supervision, NH contributed to sample and data acquisition and participated in reviewing the manuscript, SP contributed to sample and data acquisition, PJ participated in funding acquisition and supervision, KW contributed to conceptualization, reviewing, editing, and supervision. All authors read and approved the final manuscript. Funding This research was supported by the Science and Technology Human Resource Development Project, Ministry of Higher Education, Sri Lanka, funded by the Asian Development Bank (Grant No. R2RJ4). Data availability The data supporting the conclusions of this article are included as supplementary file 2. Declarations Ethics approval and consent to participate This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics review committee, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka (ERC/2023/16). Written informed consent was obtained from all participants. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Hansani Niroshika, Email: hansaniniroshika014@gmail.com. Kosala Weerakoon, Email: kosalagadw83@gmail.com. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement The data supporting the conclusions of this article are included as supplementary file 2.